in are being

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

I hereby certify that this RESPONSE TO NOTICE TO COMPLY and the documents referred to as enclosed effection are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20221

Tami Barnas

Applicant: Verdaguer, et al

Serial No.: 09/202,838

Filed: January 21, 2000

Title: CASSAVA VEIN MOSAIC VIRUS

PROMOTERS AND USES THEREOF

Group Art Unit: 1631

TECH CENTER 1600/2900 Examiner: J. Brusca

Our Ref.: TSRI 504.1

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)

NDV 1 3 201

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed August 8, 2000, enclosed is a Substitute Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Substitute Sequence Listing in computer readable form, submitted as required by 37 CFR \$1.821(e), on which the Substitute Sequence Listing is labeled MYC0011S.APP.

Entry of the following amendments and consideration of the Remarks that follow is respectfully requested.

Please amend the above-identified application as follows: